ESMO 2023 | The emerging role of liquid biopsies for gastrointestinal malignancies

Benedikt Westphalen, MD, Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany, comments on the current state of liquid biopsies for gastrointestinal cancers. Whilst questions remain regarding the precise timing of their use in the clinic, there is emerging evidence that they are beneficial in detecting genomic alterations. There is additional evidence that adjuvant chemotherapy can now be administered based on minimal residual disease (MRD) status in patients with colorectal cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.